ACCELLENA
Research & Development
2022

ACCELLENA
Clinical and non-clinical research

ACCELLENA

clinical and non-clinical research

clinical trials
human pharmacology
data science
Late phases studies overview
Since 2015, we have been organising and conducting scientific and clinical trials of drugs, implementing new methods of diagnosis and treatment in accordance with international ethical and regulatory requirements.

Being at the forefront of science, we ensure fast release and availability of the most modern medicines and means of preventing socially significant diseases.

To date, we have carried out more than 70 clinical trials in various therapeutic areas in Eastern Europe and Asia. More than 3600 subjects were included in the 15 completed late phases studies.

One of our major business lines is vaccine trials. To date we've conducted a dozen of large-scale studies of vaccines against influenza, MERS, tuberculosis, SARS and others with thousands of subjects.

latest update 05/JUL/22
Early phases studies overview
Since 2017 ACCELLENA has been organizing and conducting human pharmacology studies, including first phase studies (including first-in-human studies) and bioequivalence studies.

The company has the capacity and expertise to conduct early research into small molecules and biological products through its own Human Pharmacology Research Center (Phase I Unit).

ACCELLENA is participating in single and multiple dose escalation cohort studies, studies with “3+3” design and others.

The team has considerable experience in conducting pharmacokinetic and pharmacodynamic studies, including bioequivalence studies.

The company has studied the comparative pharmacokinetics of various dosage forms, including sprays, and also has experience in studies with pharmacodynamic end points.

latest update 05/JUL/22
Data Management
Data management (DM) services are being provided by Accellena from 2015. From 2017 we have it as in-house department.

We provide services for database and EDC development, data collection and routine data management, as well as data processing in accordance with Good Clinical Data Management Practice.

Since 2017, we have collected and processed data for more than 60 clinical trials of various phases and types, in which data from more than 10,000 study subjects were processed.

latest update 05/JUL/22
Our devotion to evidence-based medicine is fostered by our daring dream of healthy humanity expanding to space.
ACCELLENA milestones
The core of the team has gathered and started to conduct international clinical trials for world's top pharmaceutical companies in Eastern Europe.
Feb
2005
Inception
ACCELLENA company has been established and started its first international clinical trial for anti-cancer orphan drug in the USA and Europe.
Apr
2015
Foundation
Implementation of functions including in-house data science services had paved path to numerous successful clinical trials like in-hospital antibiotic resistance clinical study with around 1000 enrolled subjects.
Sep
2018
Exploration
ACCELLENA conducted more than 60 various clinical trials of all phases (including large phase III study, first-in-human vaccination study and early pharmacology trial) with 15000+ enrolled subjects up to now.
May
2022
Evolution
ACCELLENA milestones
The core of the team has gathered and started to conduct international clinical trials for world's top pharmaceutical companies in Eastern Europe.
Feb
2005
Inception
ACCELLENA company has been established and started its first international clinical trial for anti-cancer orphan drug in the USA and Europe.
Apr
2015
Foundation
Implementation of functions including in-house data science services had paved path to numerous successful clinical trials like in-hospital antibiotic resistance clinical study with around 1000 enrolled subjects.
Sep
2018
Exploration
ACCELLENA conducted more than 60 various clinical trials of all phases (including large phase III study, first-in-human vaccination study and early pharmacology trial) with 15000+ enrolled subjects up to now.
May
2022
Evolution
We are the people of Accellena
  • Konstantin Zakharov
    Management Board
    "We are passionate about creating and implementing new time and cost-effective tools and methodologies, such as comparative PK/PD studies that take a wider range of factors altering metabolism into consideration, or applying new managerial methodologies in the way we organize our research teams".
  • Artem Sergeenko
    Project Management
    "The key is integral thinking, in which each team member is aware of their unique function and area of responsibility, and at the same time, is able to perceive the health of the project in its entirety. We are strong in people and teams, this is the secret of successfully passing critical milestones of a trial and faster drug development. Isn't this what humanity needs?"
  • Maria Belavina
    QUALITY ASSURANCE
    "Quality assurance is not a matter of trust anymore, it is rather a technological challenge that is being solved today with the use of superior IT tools tailored individually for each project in compliance with GCP. And last but not the least, her majesty "discipline" - the holy grail of evidence-based medicine - rules everything."
  • Vladimir Letuchikh
    Operations
    "Natural flexibility and qualification to quickly adapt corresponding procedures to the specifics of the study is our professional necessity. This, combined with strong ties with key research centres in Russia, Europe, America and the whole world, allows us to optimise costs and make use of each invoiced hour. The more efficient we are, the healthier becomes humanity."
ACCELLENA headquarters:

Tel.: +7 (812) 337 58 66
Fax: +7 (812) 337 58 06
info@accellena.com

88, lit.A., Sredniy pr. V.O.,
St. Petersburg, Russia,
199106

Kesklinna linnaosa, Vesivärava
tn 50-201, Estonia, Tallinn,
10152